<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513719</url>
  </required_header>
  <id_info>
    <org_study_id>12-303</org_study_id>
    <nct_id>NCT02513719</nct_id>
  </id_info>
  <brief_title>XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)</brief_title>
  <official_title>XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and efficacy of XIENCE PRIME SV in real
      world practice in Japanese hospitals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on Good Post-marketing Study Practice (GPSP) regulation, general patient population
      with ischemic heart disease who are eligible for treatment with XIENCE PRIME SV Everolimus
      Eluting Stent will be registered, with no particular inclusion/exclusion criteria, and may be
      eligible for angiographic follow-up at eight months and clinical follow-up at one year.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 13, 2013</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Stent Thrombosis: Acute</measure>
    <time_frame>0-24 hours post stent implantation</time_frame>
    <description>Stent/Scaffold Thrombosis (per ARC): Stent/Scaffold Thrombosis should be reported as a cumulative value over time and at various individual time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timing:
Acute stent thrombosis: 0 to 24 hours after stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Stent Thrombosis: Subacute</measure>
    <time_frame>&gt;24 hours to 30 days post stent implantation</time_frame>
    <description>Stent/Scaffold Thrombosis (per ARC): Stent/Scaffold Thrombosis should be reported as a cumulative value over time and at various individual time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Subacute stent thrombosis : &gt;24 hours to 30 days after stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Stent Thrombosis: Late</measure>
    <time_frame>30 days to 1 year post stent implantation</time_frame>
    <description>Stent/Scaffold Thrombosis (per ARC): Stent/Scaffold Thrombosis should be reported as a cumulative value over time and at various individual time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Late stent thrombosis : &gt;30 days to 1 year after stent implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stent Thrombosis: Very Late</measure>
    <time_frame>&gt;1 year post stent implantation</time_frame>
    <description>Stent/Scaffold Thrombosis (per ARC): Stent/Scaffold Thrombosis should be reported as a cumulative value over time and at various individual time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Very late stent thrombosis : &gt;1 year after stent implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>Pre-procedure</time_frame>
    <description>The value calculated as 100 * (1- minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>post procedure (on day 0)</time_frame>
    <description>The value calculated as 100 * (1- minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>8 months</time_frame>
    <description>The value calculated as 100 * (1- minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success Rate: Percentage of Devices With Implant Success</measure>
    <time_frame>&lt; or = 1 day</time_frame>
    <description>The stent lengths used were 8 mm, 12 mm, and 15 mm,18 mm, 23 mm, and 28 mm and the stent diameter was 2.25mm.
Successful delivery and deployment of the first study scaffold/stent the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 50% by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success Rate: Percentage of Lesions With Procedural Success</measure>
    <time_frame>&lt; or = 1 day</time_frame>
    <description>Achievement of final in-scaffold/stent residual stenosis of less than 50% by QCA with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (less than or equal to 7 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success Rate: XIENCE PRIME Implant Success by Patient</measure>
    <time_frame>&lt; or = 1 day</time_frame>
    <description>The stent lengths used were 8 mm, 12 mm, and 15 mm,18 mm, 23 mm, and 28 mm and the stent diameter was 2.25 mm.
Implant success is assessed as per physicians decision, but means that the stent could be implanted at the intended location.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Death includes cardiac death, non-cardiac death and non-coronary death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death</measure>
    <time_frame>0-3 years</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death</measure>
    <time_frame>0-4 years</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death</measure>
    <time_frame>0-５ years</time_frame>
    <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>0-3 years</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>0-4 years</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>0-5 years</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization</measure>
    <time_frame>0-3 years</time_frame>
    <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization</measure>
    <time_frame>0-4 years</time_frame>
    <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization</measure>
    <time_frame>0-5 years</time_frame>
    <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>The number of patient with Ischemia-driven Target vessel revascularization (TLR or TVR, non-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</measure>
    <time_frame>0-3 years</time_frame>
    <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</measure>
    <time_frame>0-4 years</time_frame>
    <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</measure>
    <time_frame>0-5 years</time_frame>
    <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</measure>
    <time_frame>0 to 4 years</time_frame>
    <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</measure>
    <time_frame>0 to 5 years</time_frame>
    <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>0 to 4 years</time_frame>
    <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Revascularization</measure>
    <time_frame>0 to 5 years</time_frame>
    <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hemorrhage</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening:
Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention
Moderate:
Bleeding that requires blood transfusion but does not result in hemodynamic compromise
Mild:
Bleeding that does not meet criteria for either moderate or severe bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hemorrhage</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening:
Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention
Moderate:
Bleeding that requires blood transfusion but does not result in hemodynamic compromise
Mild:
Bleeding that does not meet criteria for either moderate or severe bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hemorrhage</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening:
Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention
Moderate:
Bleeding that requires blood transfusion but does not result in hemodynamic compromise
Mild:
Bleeding that does not meet criteria for either moderate or severe bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hemorrhage</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening: Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention; Moderate: Bleeding that requires blood transfusion but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either moderate or severe bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hemorrhage</measure>
    <time_frame>0 to 4 years</time_frame>
    <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening: Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention; Moderate: Bleeding that requires blood transfusion but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either moderate or severe bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hemorrhage</measure>
    <time_frame>0 to 5 years</time_frame>
    <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening: Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention; Moderate: Bleeding that requires blood transfusion but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either moderate or severe bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure</measure>
    <time_frame>0 to 4 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure</measure>
    <time_frame>0 to 5 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Death/All MI/All Revascularization</measure>
    <time_frame>0 to 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Death/All MI/All Revascularization</measure>
    <time_frame>0 to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Death/All MI/All Revascularization</measure>
    <time_frame>0 to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Death/All MI/All Revascularization</measure>
    <time_frame>0 to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Death/All MI/All Revascularization</measure>
    <time_frame>0 to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Death/All MI/All Revascularization</measure>
    <time_frame>0 to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Target vessel failure includes cardiac death, MI, ischemia driven TLR, ischemia driven TVR, non TLR and ischemia driven TVR (TLR or TVR, nonTLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure</measure>
    <time_frame>0 to 4 years</time_frame>
    <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Failure</measure>
    <time_frame>0 to 5 years</time_frame>
    <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and Clinically indicated target lesion revascularization (CI-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>0 to 4 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>0 to 5 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death or MI</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI)
Q wave MI Development of new, pathological Q wave on the ECG.
Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death or MI</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI)
Q wave MI Development of new, pathological Q wave on the ECG.
Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death or MI</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death or MI</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death or MI</measure>
    <time_frame>0 to 4 years</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death or MI</measure>
    <time_frame>0 to 5 years</time_frame>
    <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death or MI</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death or MI</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.) Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death or MI</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death or MI</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death or MI</measure>
    <time_frame>0 to 4 years</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death or MI</measure>
    <time_frame>0 to 5 years</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death or Target-Vessel MI</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death or Target Vessel-MI</measure>
    <time_frame>0 to 1 year</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death or Target Vessel MI</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death or Target Vessel MI</measure>
    <time_frame>0 to 3 years</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death or Target Vessel MI</measure>
    <time_frame>0 to 4 years</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Death or Target Vessel MI</measure>
    <time_frame>0 to 5 years</time_frame>
    <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Gain: In-stent,In-segment</measure>
    <time_frame>Pre procedure to post procedure (on day 0)</time_frame>
    <description>The acute gain was defined as the difference between post- and preprocedural minimal lumen diameter (MLD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Loss(LL): In-stent,In-segment,Proximal, and Distal</measure>
    <time_frame>8 months</time_frame>
    <description>Proximal and distal late loss was calculated by [post-procedure minimum lumen diameter (MLD)] - [MLD at 8 months].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Gain: In-stent, In-segment</measure>
    <time_frame>Post-Procedure (on day 0)</time_frame>
    <description>Difference between acute gain and late loss.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">312</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Angina Pectoris</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Occlusion</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>XIENCE PRIME SV Everolimus Eluting Coronary Stent</arm_group_label>
    <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE PRIME SV Everolimus Eluting Coronary Stent</intervention_name>
    <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
    <arm_group_label>XIENCE PRIME SV Everolimus Eluting Coronary Stent</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        General patient population with ischemic heart disease in Japan who are eligible for
        treatment with XIENCE PRIME SV Everolimus Eluting Stent will be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Patient informed consent is required for registration of this PMS. In cases where
             patient informed consent (or providing some type of information) is required for PMS
             per the participating site policy, the Sponsor will cooperate as needed.

          -  If it is known at the time of index procedure that the patient is not able to return
             for the 8-month follow-up visit for angiogram and for the 1-year clinical follow-up,
             then the patient should not be registered in the PMS.

          -  Patients who are treated (stent delivery system inserted into the body) by XIENCE
             PRIME SV will be registered (including provisional stenting for side branch treatment
             but excluding bail-out only use).

               -  The observations will be compiled on a per-patient basis even if multiple stents
                  are implanted during the index procedure.

               -  A patient whose side-branch is treated by XIENCE PRIME SV can be registered. In
                  such a case, main vessel should be treated by XIENCE PRIME.

               -  A patient who are treated by other drug eluting stent (DES) for planned stent and
                  XIENCE PRIME SV for bail-out purpose cannot be registered.

               -  Additional revascularization procedures as a part of adverse event treatment and
                  planned staged procedures will not be considered as another registration, or
                  adverse events.

               -  A patient who is treated, but failed to be implanted by XIENCE PRIME SV and
                  finally treated by other devices only (No XIENCE PRIME SV are implanted) must
                  also be registered. In such a case, only the stent information, device deficiency
                  information and reportable adverse events related to the PRIME stent, if any, are
                  required to be captured. Follow-up of the patient who does not receive any XIENCE
                  PRIME SV stent is not required.

          -  A patient may have another lesion(s) that may be treated by larger diameter stent(s).
             In such a case, treatment by XIENCE PRIME is preferable. Lesion(s) treated by other
             than XIENCE PRIME is not considered as the target lesion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Kozuma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Teikyo University Hospital, Tokyo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kimitsu Chuo Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>292-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Wajiro Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-0213</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoshi general hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>963-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsuchiya General Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Prefectural Amagasaki Hospital</name>
      <address>
        <city>Hyogo</city>
        <zip>660-0828</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsukuba Medical Center Hospital</name>
      <address>
        <city>Ibaraki</city>
        <zip>305-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishikawa Prefectual Central Hospital</name>
      <address>
        <city>Ishikawa</city>
        <zip>920-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kanagawa</city>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Kanagawa</city>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Chuo Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>862-0965</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazaki City-Gun Ishikai Hospital</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya Daini Red Cross Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>660-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart disease center Sakakibara hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka police hospital</name>
      <address>
        <city>Osaka</city>
        <zip>543-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokorozawa Heart Center</name>
      <address>
        <city>Saitama</city>
        <zip>359-1142</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokeidai memorial hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>060-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JCHO Hokkaido Hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>062-8618</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido Ohno hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>063-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sendai Kousei Hospital</name>
      <address>
        <city>Sendai</city>
        <zip>980-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okamura memorial hospital</name>
      <address>
        <city>Shizuoka</city>
        <zip>411-0904</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokushima Red Cross Hospital</name>
      <address>
        <city>Tokushima</city>
        <zip>773-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mitsui Memorial Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>101-8643</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University Hospoital</name>
      <address>
        <city>Tokyo</city>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Fujigaoka hospital</name>
      <address>
        <city>Yokohama</city>
        <zip>227-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohama City Tobu Hospital</name>
      <address>
        <city>Yokohama</city>
        <zip>230-8765</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2015</study_first_posted>
  <results_first_submitted>May 18, 2017</results_first_submitted>
  <results_first_submitted_qc>May 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2019</results_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug eluting stent</keyword>
  <keyword>stent</keyword>
  <keyword>real world</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 312 subjects were enrolled from 30 sites. The enrollment period was from May 13, 2013 to March 25, 2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
          <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>At 8 Months Clinical Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>At 1 Year Clinical Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>At 2 Years Clinical Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>At 3 Years Clinical Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>At 4 Years Clinical Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>At 5 Years Clinical Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>312 patients from 30 sites were treated with PRIME SV</population>
      <group_list>
        <group group_id="B1">
          <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
          <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="312"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.6" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Stent Thrombosis: Acute</title>
        <description>Stent/Scaffold Thrombosis (per ARC): Stent/Scaffold Thrombosis should be reported as a cumulative value over time and at various individual time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timing:
Acute stent thrombosis: 0 to 24 hours after stent implantation</description>
        <time_frame>0-24 hours post stent implantation</time_frame>
        <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis: Acute</title>
          <description>Stent/Scaffold Thrombosis (per ARC): Stent/Scaffold Thrombosis should be reported as a cumulative value over time and at various individual time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timing:
Acute stent thrombosis: 0 to 24 hours after stent implantation</description>
          <population>Intent-To-Treat Population set (ITT). The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Stent Thrombosis: Subacute</title>
        <description>Stent/Scaffold Thrombosis (per ARC): Stent/Scaffold Thrombosis should be reported as a cumulative value over time and at various individual time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Subacute stent thrombosis : &gt;24 hours to 30 days after stent implantation</description>
        <time_frame>&gt;24 hours to 30 days post stent implantation</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis: Subacute</title>
          <description>Stent/Scaffold Thrombosis (per ARC): Stent/Scaffold Thrombosis should be reported as a cumulative value over time and at various individual time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Subacute stent thrombosis : &gt;24 hours to 30 days after stent implantation</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Stent Thrombosis: Late</title>
        <description>Stent/Scaffold Thrombosis (per ARC): Stent/Scaffold Thrombosis should be reported as a cumulative value over time and at various individual time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Late stent thrombosis : &gt;30 days to 1 year after stent implantation</description>
        <time_frame>30 days to 1 year post stent implantation</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis: Late</title>
          <description>Stent/Scaffold Thrombosis (per ARC): Stent/Scaffold Thrombosis should be reported as a cumulative value over time and at various individual time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Late stent thrombosis : &gt;30 days to 1 year after stent implantation</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stent Thrombosis: Very Late</title>
        <description>Stent/Scaffold Thrombosis (per ARC): Stent/Scaffold Thrombosis should be reported as a cumulative value over time and at various individual time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Very late stent thrombosis : &gt;1 year after stent implantation.</description>
        <time_frame>&gt;1 year post stent implantation</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stent Thrombosis: Very Late</title>
          <description>Stent/Scaffold Thrombosis (per ARC): Stent/Scaffold Thrombosis should be reported as a cumulative value over time and at various individual time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Very late stent thrombosis : &gt;1 year after stent implantation.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Diameter Stenosis (%DS)</title>
        <description>The value calculated as 100 * (1- minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
        <time_frame>Pre-procedure</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis (%DS)</title>
          <description>The value calculated as 100 * (1- minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
          <population>ITT population.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions QCA</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions QCA</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.62" spread="16.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Diameter Stenosis (%DS)</title>
        <description>The value calculated as 100 * (1- minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
        <time_frame>post procedure (on day 0)</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis (%DS)</title>
          <description>The value calculated as 100 * (1- minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
          <population>ITT population.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions QCA</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions QCA</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.03" spread="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Diameter Stenosis (%DS)</title>
        <description>The value calculated as 100 * (1- minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
        <time_frame>8 months</time_frame>
        <population>The number of participants analyzed includes subjects who received angiographic follow-up at 8 months.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis (%DS)</title>
          <description>The value calculated as 100 * (1- minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
          <population>The number of participants analyzed includes subjects who received angiographic follow-up at 8 months.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.31" spread="17.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate: Percentage of Devices With Implant Success</title>
        <description>The stent lengths used were 8 mm, 12 mm, and 15 mm,18 mm, 23 mm, and 28 mm and the stent diameter was 2.25mm.
Successful delivery and deployment of the first study scaffold/stent the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 50% by quantitative coronary angiography (QCA).</description>
        <time_frame>&lt; or = 1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate: Percentage of Devices With Implant Success</title>
          <description>The stent lengths used were 8 mm, 12 mm, and 15 mm,18 mm, 23 mm, and 28 mm and the stent diameter was 2.25mm.
Successful delivery and deployment of the first study scaffold/stent the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 50% by quantitative coronary angiography (QCA).</description>
          <units>percentage of devices</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>XIENCE PRIME SV stents</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>XIENCE PRIME SV stents</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate: Percentage of Lesions With Procedural Success</title>
        <description>Achievement of final in-scaffold/stent residual stenosis of less than 50% by QCA with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (less than or equal to 7 days).</description>
        <time_frame>&lt; or = 1 day</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate: Percentage of Lesions With Procedural Success</title>
          <description>Achievement of final in-scaffold/stent residual stenosis of less than 50% by QCA with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (less than or equal to 7 days).</description>
          <population>ITT population.</population>
          <units>Percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate: XIENCE PRIME Implant Success by Patient</title>
        <description>The stent lengths used were 8 mm, 12 mm, and 15 mm,18 mm, 23 mm, and 28 mm and the stent diameter was 2.25 mm.
Implant success is assessed as per physicians decision, but means that the stent could be implanted at the intended location.</description>
        <time_frame>&lt; or = 1 day</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate: XIENCE PRIME Implant Success by Patient</title>
          <description>The stent lengths used were 8 mm, 12 mm, and 15 mm,18 mm, 23 mm, and 28 mm and the stent diameter was 2.25 mm.
Implant success is assessed as per physicians decision, but means that the stent could be implanted at the intended location.</description>
          <population>ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death</title>
        <description>Death includes cardiac death, non-cardiac death and non-coronary death.</description>
        <time_frame>0 to 8 months</time_frame>
        <population>Intent-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death</title>
          <description>Death includes cardiac death, non-cardiac death and non-coronary death.</description>
          <population>Intent-to-treat (ITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>Intent-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>Intent-to-treat (ITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0-3 years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0-4 years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death</title>
        <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0-５ years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death</title>
          <description>All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.
• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0-3 years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0-4 years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0-5 years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization</title>
        <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization</title>
          <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization</title>
        <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization</title>
          <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization</title>
        <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization</title>
          <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization</title>
        <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
        <time_frame>0-3 years</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization</title>
          <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization</title>
        <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
        <time_frame>0-4 years</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization</title>
          <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization</title>
        <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
        <time_frame>0-5 years</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization</title>
          <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</title>
        <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</title>
          <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</title>
        <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</title>
          <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</title>
        <description>The number of patient with Ischemia-driven Target vessel revascularization (TLR or TVR, non-TLR)</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</title>
          <description>The number of patient with Ischemia-driven Target vessel revascularization (TLR or TVR, non-TLR)</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</title>
        <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
        <time_frame>0-3 years</time_frame>
        <population>ITT popuation</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</title>
          <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
          <population>ITT popuation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</title>
        <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
        <time_frame>0-4 years</time_frame>
        <population>ITT popuation</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</title>
          <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
          <population>ITT popuation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</title>
        <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
        <time_frame>0-5 years</time_frame>
        <population>ITT popuation</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TLR or TVR, Non-TLR)</title>
          <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR, non-TLR) or non-ischemia driven TVR (TLR or TVR, non-TLR)</description>
          <population>ITT popuation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</title>
        <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</title>
          <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</title>
        <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</title>
          <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</title>
        <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</title>
          <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</title>
        <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</title>
          <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</title>
        <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
        <time_frame>0 to 4 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</title>
          <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</title>
        <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
        <time_frame>0 to 5 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-target Vessel Revascularization (Non-TVR)</title>
          <description>Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularization</title>
          <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularization</title>
          <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularization</title>
          <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularization</title>
          <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
        <time_frame>0 to 4 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularization</title>
          <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Revascularization</title>
        <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
        <time_frame>0 to 5 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Revascularization</title>
          <description>Revascularization:
Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.
Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.
Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hemorrhage</title>
        <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening:
Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention
Moderate:
Bleeding that requires blood transfusion but does not result in hemodynamic compromise
Mild:
Bleeding that does not meet criteria for either moderate or severe bleeding</description>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hemorrhage</title>
          <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening:
Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention
Moderate:
Bleeding that requires blood transfusion but does not result in hemodynamic compromise
Mild:
Bleeding that does not meet criteria for either moderate or severe bleeding</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hemorrhage</title>
        <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening:
Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention
Moderate:
Bleeding that requires blood transfusion but does not result in hemodynamic compromise
Mild:
Bleeding that does not meet criteria for either moderate or severe bleeding</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hemorrhage</title>
          <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening:
Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention
Moderate:
Bleeding that requires blood transfusion but does not result in hemodynamic compromise
Mild:
Bleeding that does not meet criteria for either moderate or severe bleeding</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hemorrhage</title>
        <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening:
Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention
Moderate:
Bleeding that requires blood transfusion but does not result in hemodynamic compromise
Mild:
Bleeding that does not meet criteria for either moderate or severe bleeding</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hemorrhage</title>
          <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening:
Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention
Moderate:
Bleeding that requires blood transfusion but does not result in hemodynamic compromise
Mild:
Bleeding that does not meet criteria for either moderate or severe bleeding</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hemorrhage</title>
        <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening: Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention; Moderate: Bleeding that requires blood transfusion but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either moderate or severe bleeding.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hemorrhage</title>
          <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening: Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention; Moderate: Bleeding that requires blood transfusion but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either moderate or severe bleeding.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hemorrhage</title>
        <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening: Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention; Moderate: Bleeding that requires blood transfusion but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either moderate or severe bleeding.</description>
        <time_frame>0 to 4 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hemorrhage</title>
          <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening: Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention; Moderate: Bleeding that requires blood transfusion but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either moderate or severe bleeding.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hemorrhage</title>
        <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening: Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention; Moderate: Bleeding that requires blood transfusion but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either moderate or severe bleeding.</description>
        <time_frame>0 to 5 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hemorrhage</title>
          <description>Bleeding complications will be defined according to the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) classification of severe, moderate, and mild bleeding events.
Severe or life-threatening: Either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention; Moderate: Bleeding that requires blood transfusion but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either moderate or severe bleeding.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 4 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 5 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Death/All MI/All Revascularization</title>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Death/All MI/All Revascularization</title>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Death/All MI/All Revascularization</title>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Death/All MI/All Revascularization</title>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Death/All MI/All Revascularization</title>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Death/All MI/All Revascularization</title>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Death/All MI/All Revascularization</title>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Death/All MI/All Revascularization</title>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Death/All MI/All Revascularization</title>
        <time_frame>0 to 4 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Death/All MI/All Revascularization</title>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Death/All MI/All Revascularization</title>
        <time_frame>0 to 5 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Death/All MI/All Revascularization</title>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure</title>
        <description>Target vessel failure includes cardiac death, MI, ischemia driven TLR, ischemia driven TVR, non TLR and ischemia driven TVR (TLR or TVR, nonTLR).</description>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure</title>
          <description>Target vessel failure includes cardiac death, MI, ischemia driven TLR, ischemia driven TVR, non TLR and ischemia driven TVR (TLR or TVR, nonTLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure</title>
        <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure</title>
          <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure</title>
        <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure</title>
          <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure</title>
        <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure</title>
          <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure</title>
        <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
        <time_frame>0 to 4 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure</title>
          <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Failure</title>
        <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
        <time_frame>0 to 5 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Failure</title>
          <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, nonTLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Adverse Cardiac Events (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and Clinically indicated target lesion revascularization (CI-TLR).</description>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Cardiac Events (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and Clinically indicated target lesion revascularization (CI-TLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Adverse Cardiac Events (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Cardiac Events (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Adverse Cardiac Events (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Cardiac Events (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Adverse Cardiac Events (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Cardiac Events (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Adverse Cardiac Events (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
        <time_frame>0 to 4 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Cardiac Events (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Adverse Cardiac Events (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
        <time_frame>0 to 5 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Cardiac Events (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and clinically indicated target lesion revascularization (CI-TLR).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death or MI</title>
        <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI)
Q wave MI Development of new, pathological Q wave on the ECG.
Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death or MI</title>
          <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI)
Q wave MI Development of new, pathological Q wave on the ECG.
Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death or MI</title>
        <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI)
Q wave MI Development of new, pathological Q wave on the ECG.
Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death or MI</title>
          <description>All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI)
Q wave MI Development of new, pathological Q wave on the ECG.
Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death or MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death or MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death or MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death or MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death or MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
        <time_frame>0 to 4 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death or MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death or MI</title>
        <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
        <time_frame>0 to 5 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death or MI</title>
          <description>All deaths includes Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death or MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death or MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death or MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.) Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death or MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.) Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death or MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death or MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death or MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death or MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death or MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 4 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death or MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death or MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
        <time_frame>0 to 5 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death or MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death or Target-Vessel MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
        <time_frame>0 to 8 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death or Target-Vessel MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death or Target Vessel-MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
        <time_frame>0 to 1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death or Target Vessel-MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death or Target Vessel MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
        <time_frame>0 to 2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death or Target Vessel MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death or Target Vessel MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
        <time_frame>0 to 3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death or Target Vessel MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death or Target Vessel MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
        <time_frame>0 to 4 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death or Target Vessel MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Death or Target Vessel MI</title>
        <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
        <time_frame>0 to 5 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Death or Target Vessel MI</title>
          <description>Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).</description>
          <population>ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Gain: In-stent,In-segment</title>
        <description>The acute gain was defined as the difference between post- and preprocedural minimal lumen diameter (MLD).</description>
        <time_frame>Pre procedure to post procedure (on day 0)</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Gain: In-stent,In-segment</title>
          <description>The acute gain was defined as the difference between post- and preprocedural minimal lumen diameter (MLD).</description>
          <population>ITT population.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Loss(LL): In-stent,In-segment,Proximal, and Distal</title>
        <description>Proximal and distal late loss was calculated by [post-procedure minimum lumen diameter (MLD)] - [MLD at 8 months].</description>
        <time_frame>8 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Late Loss(LL): In-stent,In-segment,Proximal, and Distal</title>
          <description>Proximal and distal late loss was calculated by [post-procedure minimum lumen diameter (MLD)] - [MLD at 8 months].</description>
          <population>ITT population</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Gain: In-stent, In-segment</title>
        <description>Difference between acute gain and late loss.</description>
        <time_frame>Post-Procedure (on day 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
            <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Net Gain: In-stent, In-segment</title>
          <description>Difference between acute gain and late loss.</description>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>XIENCE PRIME SV Everolimus Eluting Coronary Stent</title>
          <description>Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
XIENCE PRIME SV Everolimus Eluting Coronary Stent: Patients receiving XIENCE PRIME SV Everolimus Eluting Stent</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Heart failures</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Aortic regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Complete AV block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis intestinal hemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Ischemic colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Lower digestive tract haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gastric ulcer hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Large intestine hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Device related thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Femoral fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Shunt stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Exercise test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Type II diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot Deformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Myelodysplastic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Pancreatic Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Prostatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Ureter cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Metastatic liver cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Metastatic prostatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Cerebral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Ischiadic nerve neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Nephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Interstitial pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kusano Hajime</name_or_title>
      <organization>Abbott Vascular</organization>
      <email>hajime.kusano@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

